IBDEI200 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31886,1,4,0)
 ;;=4^N30.10
 ;;^UTILITY(U,$J,358.3,31886,2)
 ;;=^5015634
 ;;^UTILITY(U,$J,358.3,31887,0)
 ;;=N30.90^^126^1634^13
 ;;^UTILITY(U,$J,358.3,31887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31887,1,3,0)
 ;;=3^Cystitis w/o Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,31887,1,4,0)
 ;;=4^N30.90
 ;;^UTILITY(U,$J,358.3,31887,2)
 ;;=^5015642
 ;;^UTILITY(U,$J,358.3,31888,0)
 ;;=N30.91^^126^1634^12
 ;;^UTILITY(U,$J,358.3,31888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31888,1,3,0)
 ;;=3^Cystitis w/ Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,31888,1,4,0)
 ;;=4^N30.91
 ;;^UTILITY(U,$J,358.3,31888,2)
 ;;=^5015643
 ;;^UTILITY(U,$J,358.3,31889,0)
 ;;=N81.11^^126^1634^15
 ;;^UTILITY(U,$J,358.3,31889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31889,1,3,0)
 ;;=3^Cystocele,Midline
 ;;^UTILITY(U,$J,358.3,31889,1,4,0)
 ;;=4^N81.11
 ;;^UTILITY(U,$J,358.3,31889,2)
 ;;=^331534
 ;;^UTILITY(U,$J,358.3,31890,0)
 ;;=R30.0^^126^1634^16
 ;;^UTILITY(U,$J,358.3,31890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31890,1,3,0)
 ;;=3^Dysuria
 ;;^UTILITY(U,$J,358.3,31890,1,4,0)
 ;;=4^R30.0
 ;;^UTILITY(U,$J,358.3,31890,2)
 ;;=^5019322
 ;;^UTILITY(U,$J,358.3,31891,0)
 ;;=N80.1^^126^1634^17
 ;;^UTILITY(U,$J,358.3,31891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31891,1,3,0)
 ;;=3^Endometriosis of Ovary
 ;;^UTILITY(U,$J,358.3,31891,1,4,0)
 ;;=4^N80.1
 ;;^UTILITY(U,$J,358.3,31891,2)
 ;;=^270484
 ;;^UTILITY(U,$J,358.3,31892,0)
 ;;=N73.9^^126^1634^18
 ;;^UTILITY(U,$J,358.3,31892,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31892,1,3,0)
 ;;=3^Female Pelvic Inflammatory Disease,Unspec
 ;;^UTILITY(U,$J,358.3,31892,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,31892,2)
 ;;=^5015820
 ;;^UTILITY(U,$J,358.3,31893,0)
 ;;=R35.0^^126^1634^21
 ;;^UTILITY(U,$J,358.3,31893,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31893,1,3,0)
 ;;=3^Frequency of Micturition
 ;;^UTILITY(U,$J,358.3,31893,1,4,0)
 ;;=4^R35.0
 ;;^UTILITY(U,$J,358.3,31893,2)
 ;;=^5019334
 ;;^UTILITY(U,$J,358.3,31894,0)
 ;;=R39.14^^126^1634^24
 ;;^UTILITY(U,$J,358.3,31894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31894,1,3,0)
 ;;=3^Incomplete Voiding
 ;;^UTILITY(U,$J,358.3,31894,1,4,0)
 ;;=4^R39.14
 ;;^UTILITY(U,$J,358.3,31894,2)
 ;;=^5019344
 ;;^UTILITY(U,$J,358.3,31895,0)
 ;;=R31.1^^126^1634^25
 ;;^UTILITY(U,$J,358.3,31895,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31895,1,3,0)
 ;;=3^Microscopic Hematuria
 ;;^UTILITY(U,$J,358.3,31895,1,4,0)
 ;;=4^R31.1
 ;;^UTILITY(U,$J,358.3,31895,2)
 ;;=^5019326
 ;;^UTILITY(U,$J,358.3,31896,0)
 ;;=N20.0^^126^1634^30
 ;;^UTILITY(U,$J,358.3,31896,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31896,1,3,0)
 ;;=3^Neprolithiasis
 ;;^UTILITY(U,$J,358.3,31896,1,4,0)
 ;;=4^N20.0
 ;;^UTILITY(U,$J,358.3,31896,2)
 ;;=^67056
 ;;^UTILITY(U,$J,358.3,31897,0)
 ;;=R35.1^^126^1634^31
 ;;^UTILITY(U,$J,358.3,31897,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31897,1,3,0)
 ;;=3^Nocturia
 ;;^UTILITY(U,$J,358.3,31897,1,4,0)
 ;;=4^R35.1
 ;;^UTILITY(U,$J,358.3,31897,2)
 ;;=^5019335
 ;;^UTILITY(U,$J,358.3,31898,0)
 ;;=N83.8^^126^1634^32
 ;;^UTILITY(U,$J,358.3,31898,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31898,1,3,0)
 ;;=3^Noninflammatory Disorder of Ovary,Fallop & Broad Ligmt
 ;;^UTILITY(U,$J,358.3,31898,1,4,0)
 ;;=4^N83.8
 ;;^UTILITY(U,$J,358.3,31898,2)
 ;;=^5015864
 ;;^UTILITY(U,$J,358.3,31899,0)
 ;;=N39.8^^126^1634^56
 ;;^UTILITY(U,$J,358.3,31899,1,0)
 ;;=^358.31IA^4^2
